Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.

In contrast to the data in Figure 1 , VSV-SARS-Mem generated highly significant therapy following direct IT delivery in mice previously vaccinated with the SC-Ad-MN vector ( Figure 2 B).

also in 132,142 other papers